DYN
Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) has 13 SEC Form 4 filings (75 transaction rows) in the rolling window, disclosed by 6 distinct insiders. Most recent filing: Jul 8, 2026.
The most active filer is Director Rhodes Jason P with 16 filings. Insiders have net sold $67.0M over the trailing 6 months.
- Industry:Biotechnology
- CEO:John G. Cox
- Employees:192
- HQ:Waltham, MA, US
- IPO:2020-09-17
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$67.0M
reported sales (SEC code S)
Unique Insiders
6
in the rolling window
Market Cap
$4.0B
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| Director | Sale | 480,240 | $10.9M | Jul 8 | SEC ↗ | |
| Director | Sale | 297,211 | $6.9M | Jul 8 | SEC ↗ | |
| Director | Sale | 309,268 | $6.6M | Jun 30 | SEC ↗ | |
| Director | Sale | 195,427 | $4.1M | Jun 30 | SEC ↗ | |
| Director | Sale | 147,760 | $3.1M | Jun 26 | SEC ↗ | |
| Director | Sale | 95,900 | $2.0M | Jun 26 | SEC ↗ | |
| Director | Sale | 24,100 | $509K | Jun 26 | SEC ↗ | |
Lucera ErickFirst filing | Chief Financial Officer | Sale | 2,362 | $48K | Jun 26 | SEC ↗ |
| Director | Sale | 190,676 | $3.9M | Jun 24 | SEC ↗ | |
| Director | Sale | 73,286 | $1.5M | Jun 24 | SEC ↗ | |
Kersten DirkFirst filing | Director | Sale | 37,454 | $754K | Jun 22 | SEC ↗ |
Kersten DirkFirst filing | Director | Sale | 46,901 | $941K | Jun 22 | SEC ↗ |
Friedl-Naderer JohannaFirst filing | Chief Commercial Officer | Sale | 145 | $3K | Jun 17 | SEC ↗ |
Cox JohnFirst filing | CEO & President | Sale | 2,683 | $49K | Jun 17 | SEC ↗ |
Kerr DouglasFirst filing | Chief Medical Officer | Sale | 887 | $16K | Jun 17 | SEC ↗ |
| Director | Sale | 11,904 | $214K | May 6 | SEC ↗ | |
| Director | Sale | 11,600 | $209K | May 6 | SEC ↗ | |
| Director | Sale | 83,219 | $1.5M | May 6 | SEC ↗ | |
| Insider | Sale | 73,108 | $1.4M | Apr 27 | SEC ↗ | |
| Insider | Sale | 137,948 | $2.5M | Apr 27 | SEC ↗ | |
| Insider | Sale | 173,493 | $3.1M | Apr 27 | SEC ↗ | |
Rhodes Jason PFirst filing | Insider | Sale | 272,049 | $5.5M | Apr 22 | SEC ↗ |
Rhodes Jason PFirst filing | Insider | Sale | 274,297 | $5.4M | Apr 22 | SEC ↗ |
Rhodes Jason PFirst filing | Insider | Sale | 287,956 | $5.7M | Apr 22 | SEC ↗ |
Related companies
Dyne Therapeutics, Inc. is in the Healthcare sector.